PF-06439535 (CN)

DRUG2 trials

Sponsors

Pfizer

Conditions

Advanced Non-squamous NSCLCPharmacokinetics

Phase 1

A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS

WithdrawnNCT04126044

PfizerPharmacokinetics

Start: 2021-01-22End: 2021-07-10Updated: 2021-04-27

Phase 3

A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

TerminatedNCT04325698

PfizerAdvanced Non-squamous NSCLC

Start: 2020-06-11End: 2021-05-10Updated: 2024-10-01